Chest
Volume 143, Issue 6, June 2013, Pages 1750-1757
Journal home page for Chest

Translating Basic Research into Clinical Practice
Efferocytosis and Lung Disease

https://doi.org/10.1378/chest.12-2413Get rights and content

In healthy individuals, billions of cells die by apoptosis each day. Clearance of these apoptotic cells, termed “efferocytosis,” must be efficient to prevent secondary necrosis and the release of proinflammatory cell contents that disrupt tissue homeostasis and potentially foster autoimmunity. During inflammation, most apoptotic cells are cleared by macrophages; the efferocytic process actively induces a macrophage phenotype that favors tissue repair and suppression of inflammation. Several chronic lung diseases, particularly airways diseases such as chronic obstructive lung disease, asthma, and cystic fibrosis, are characterized by an increased lung burden of uningested apoptotic cells. Alveolar macrophages from individuals with these chronic airways diseases have decreased efferocytosis relative to alveolar macrophages from healthy subjects. These two findings have led to the hypothesis that impaired apoptotic cell clearance may contribute causally to sustained lung inflammation and that therapies to enhance efferocytosis might be beneficial. This review of the English-language scientific literature (2006 to mid-2012) explains how such existing therapies as corticosteroids, statins, and macrolides may act in part by augmenting apoptotic cell clearance. However, efferocytosis can also impede host defenses against lung infection. Thus, determining whether novel therapies to augment efferocytosis should be developed and in whom they should be used lies at the heart of efforts to differentiate specific phenotypes within complex chronic lung diseases to provide appropriately personalized therapies.

Section snippets

Mechanisms of Efferocytosis

Efferocytosis is a regulated, evolutionarily conserved process requiring phagocyte migration, adhesion, and ingestion. Apoptotic cells actively recruit mononuclear phagocytes by secreting chemotaxins and further identify themselves by shifting both surface glycoprotein composition and the basal asymmetry of their membrane lipids, displaying phosphatidylserine (PS) and other molecules.6 Møs and DCs bind PS either directly, using receptors such as TIM-4 and brain angiogenesis inhibitor 1, or

Immune Consequences of Efferocytosis

Besides preventing release of alarmins during secondary necrosis, efferocytosis profoundly impacts phagocyte function.13 Efferocytosis was initially believed to be invariably antiinflammatory or tolerogenic but is now recognized to induce more complex responses. Strong evolutionary pressure has assured that efferocytosis permits maintenance of tolerance to host molecules while allowing generation of immune responses to infected apoptotic cells. How phagocytes achieve these potentially

Alveolar and Interstitial Lung Møs

Alveolar Møs (AMøs) are the most numerous professional phagocyte of the alveolar space and the most commonly studied. In healthy individuals, AMøs comprise 90% to 95% of cells recovered from BAL. Although AMøs avidly ingest many types of particles, they engulf apoptotic cells poorly when compared with other tissue Møs.8 Several factors contribute to reduced efferocytosis by AMø, including reduced adhesion, very low expression of protein kinase C βII, and inhibition by the lung collectins

COPD

COPD is increasingly recognized to result from several pathologic processes, including loss of airway luminal diameter due to mucus gland hyperplasia and peribronchial fibrosis; pan-alveolar destruction; and, recently, small airways disappearance.38 The clinical phenotype in a given patient with COPD results from variable involvement of these processes, several of which, especially emphysema, are characterized by apoptosis of lung structural cells. Neutrophils, recruited by IL-8 and by

Common Respiratory Drugs

Efferocytosis by human and murine AMøs is significantly increased by in vitro treatment with clinically relevant doses of statins, macrolides, or corticosteroids.31., 40., 42., 55., 56. In mice, this effect of statins has also been demonstrated in vivo; it appears to be mediated by RhoA inhibition (thereby allowing activation of Rac-1, which is necessary for efferocytosis).56 Corticosteroids increase AMø efferocytosis by two processes: one rapid and dependent largely on SIRPα down-regulation;

Conclusions

Enhancing the defective efferocytosis seen in multiple lung diseases and active cigarette smoking is a plausible means to arrest ongoing lung inflammation. Improved efferocytosis may contribute to beneficial actions of existing therapies, such as inhaled steroids, macrolides, and statins. Better understanding of the molecular basis for the immunomodulatory effects of efferocytosis could lead to entirely novel therapies. Further investigation is needed to determine the true impact of enhancing

Acknowledgments

Financial/nonfinancial disclosures: The authors have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Role of sponsors: The funding agencies had no role beyond financial support in the preparation of this manuscript. The opinions expressed are those of the authors and do not reflect the position of the Department of Veterans Affairs.

Other contributions: We thank David M. Aronoff, MD; Gary

References (63)

  • M Inoue et al.

    Carbocisteine promotes phagocytosis of apoptotic cells by alveolar macrophages

    Eur J Pharmacol

    (2012)
  • MJ Joo et al.

    Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD

    Respir Med

    (2010)
  • EP Schmidt et al.

    Role of apoptosis in amplifying inflammatory responses in lung diseases

    J Cell Death

    (2010)
  • SJ Schwulst et al.

    Bim siRNA decreases lymphocyte apoptosis and improves survival in sepsis

    Shock

    (2008)
  • D Korns et al.

    Modulation of macrophage efferocytosis in inflammation

    Front Immunol

    (2011)
  • PM Henson et al.

    State of the art. Apoptosis and cell homeostasis in chronic obstructive pulmonary disease

    Proc Am Thorac Soc

    (2006)
  • C Peter et al.

    Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells

    Apoptosis

    (2010)
  • G Lemke et al.

    Immunobiology of the TAM receptors

    Nat Rev Immunol

    (2008)
  • JL Curtis et al.

    Tyro3 receptor tyrosine kinases in the heterogeneity of apoptotic cell uptake

    Front Biosci

    (2009)
  • L Mukundan et al.

    PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance

    Nat Med

    (2009)
  • T Roszer et al.

    Autoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency

    J Immunol

    (2011)
  • A Devitt et al.

    The innate immune system and the clearance of apoptotic cells

    J Leukoc Biol

    (2011)
  • MT Silva

    Macrophage phagocytosis of neutrophils at inflammatory/infectious foci: a cooperative mechanism in the control of infection and infectious inflammation

    J Leukoc Biol

    (2011)
  • P Gurung et al.

    Immune unresponsiveness to secondary heterologous bacterial infection after sepsis induction is TRAIL dependent

    J Immunol

    (2011)
  • WJ Janssen et al.

    Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha

    Am J Respir Crit Care Med

    (2008)
  • K Miles et al.

    Dying and necrotic neutrophils are anti-inflammatory secondary to the release of alpha-defensins

    J Immunol

    (2009)
  • HN Li et al.

    Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages

    J Leukoc Biol

    (2009)
  • YQ Xiao et al.

    Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells

    J Immunol

    (2008)
  • K Köröskényi et al.

    Involvement of adenosine A2A receptors in engulfment-dependent apoptotic cell suppression of inflammation

    J Immunol

    (2011)
  • MN Sharif et al.

    Twist mediates suppression of inflammation by type I IFNs and Axl

    J Exp Med

    (2006)
  • AI Medeiros et al.

    Efferocytosis impairs pulmonary macrophage and lung antibacterial function via PGE2/EP2 signaling

    J Exp Med

    (2009)
  • Cited by (0)

    Funding/Support: This work was supported by the National Institutes of Health [Grants U01 HL098961, R01 HL056309, and R01 HL082480] and by a Research Enhancement Award Program from the Biomedical Laboratory Research and Development Service, Department of Veterans Affairs.

    Reproduction of this article is prohibited without written permission from the American College of Chest Physicians. See online for more details.

    View full text